Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura

Massimo Cugno, Ilaria Mancini, Dario Consonni, Valentina De Zan, Gianluigi Ardissino, Samantha Griffini, Elena Grovetti, Luigi Porcaro, Barbara Ferrari, Andrea Artoni, Flora Peyvandi

Blood (2023) 141 (18): 2278–2282.

https://doi.org/10.1182/blood.2022018644

Published: 2023

Includes: Supplemental data

Journal Articles

Characterization of Patients with aHUS and Triggering/Associated Events, with and without Complement Pathogenic Variants or Anti-Cfh Antibodies: A Global aHUS Registry Analysis

Andrew Siedlecki, Imad Al-Dakkak, Katerina Anokhina, Nicole Isbel, Véronique Frémeaux-Bacchi, Rodney Gilbert, Laurence Greenbaum, Gema Ariceta, Gianluigi Ardissino, Franz Schaefer, Eric Rondeau, Christoph Licht

Blood (2022) 140 (Supplement 1): 2767–2769.

https://doi.org/10.1182/blood-2022-155814

Published: 2022

Journal Articles

The Global aHUS Registry: Characteristics of 826 Patients with Atypical Hemolytic Uremic Syndrome

Christoph Licht, MD FRCP(C), FASN, Gianluigi Ardissino, MD PhD, Gema Ariceta, MD PhD, David J. Cohen, MD, Christoph Gasteyger, MD, Laurence A. Greenbaum, MDPhD, Masayo Ogawa, MD FAAP, Varant Kupelian, PhD, Franz Schaefer, MD, Johan Vande Walle, MD PhD, Véronique Frémeaux-Bacchi, MD PhD

Blood (2015) 126 (23): 4640.

https://doi.org/10.1182/blood.V126.23.4640.4640

Published: 2015

Journal Articles

Baseline Demographics and Characteristics of 466 Patients with Atypical Hemolytic Uremic Syndrome in the Global aHUS Registry

Christoph Licht, MD FRCP(C), FASN, Gianluigi Ardissino, MD PhD, Gema Ariceta, MD PhD, David Cohen, MD, Christoph Gasteyger, MD, Laurence A. Greenbaum, MDPhD, Masayo Ogawa, MD FAAP, Franz Schaefer, MD, Johan Vande Walle, MD PhD, Veronique Fremeaux-Bacchi, MD PhD

Blood (2014) 124 (21): 4204.

https://doi.org/10.1182/blood.V124.21.4204.4204

Published: 2014

Journal Articles

Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update

Laurence A. Greenbaum, MDPhD, Marc Fila, MD PhD, Gianluigi Ardissino, MD PhD, Samhar I. Al-Akash, MD, Jonathan H Evans, MD, Kenneth Lieberman, MD, Silvio Maringhini, MD, Lars Pape, MD, Lesley Rees, MD FRCPCH, Nicole C.A.J. van de Kar, MD PhD, Johan Vande Walle, MD PhD, Masayo Ogawa, MD FAAP, Camille L. Bedrosian, MD, Christoph Licht, MD FRCP(C), FASN

Blood (2014) 124 (21): 4986.

https://doi.org/10.1182/blood.V124.21.4986.4986

Published: 2014

Journal Articles

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Larry Greenbaum, MD, Marc Fila, Gianluigi Ardissino, Samhar Al-Akash, Jonathan Evans, Paul Henning, Kenneth Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, Nicole Kar, Johan Vande Walle, Masayo Ogawa, MD, FAAP, Camille L. Bedrosian, MD, Christoph Licht, MD

Blood (2013) 122 (21): 2191.

https://doi.org/10.1182/blood.V122.21.2191.2191

Published: 2013

NARROW

Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura

Characterization of Patients with aHUS and Triggering/Associated Events, with and without Complement Pathogenic Variants or Anti-Cfh Antibodies: A Global aHUS Registry Analysis

The Global aHUS Registry: Characteristics of 826 Patients with Atypical Hemolytic Uremic Syndrome

Baseline Demographics and Characteristics of 466 Patients with Atypical Hemolytic Uremic Syndrome in the Global aHUS Registry

Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Email alerts

ASH Publications

American Society of Hematology

Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura

Characterization of Patients with aHUS and Triggering/Associated Events, with and without Complement Pathogenic Variants or Anti-Cfh Antibodies: A Global aHUS Registry Analysis

The Global aHUS Registry: Characteristics of 826 Patients with Atypical Hemolytic Uremic Syndrome

Baseline Demographics and Characteristics of 466 Patients with Atypical Hemolytic Uremic Syndrome in the Global aHUS Registry

Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only